Defence Therapeutics is a publicly-traded (CSE: DTC, OTCQB: DTCFF, FSE: DTC) clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious
diseases.
Company Details
- Employees
- 5
- Address
- 7171 Rue Frederick-Banting, Montreal,quebec H4s 1z9,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Montreal, Quebec
Defence Therapeutics Questions
Defence Therapeutics's website is http://www.defencetherapeutics.com
Defence Therapeutics's LinkedIn profile is https://ca.linkedin.com/company/defence-therapeutics
Defence Therapeutics has
5 employees.
View email and phone details for 5
employees at Defence Therapeutics.
Defence Therapeutics's industry is
Biotechnology Research
Defence Therapeutics's top competitors are
Repare Therapeutics,
Ebovir Biotechnologie Inc.,
Alpha-9 Oncology,
Telescope Therapeutics,
Odyssey Therapeutics,
35pharma,
Reverb Therapeutics,
Targa Biomedical,
Wassc Tech Inc,
Admare Bioinnovations.
Defence Therapeutics's categories are Biotechnology Research
